Patent · US Active

Methods of treating myointimal proliferation

US11364284B2 · kind B2 · utility

1Cited by

4References

18Claims

0Family size

Assignees

Inozyme Pharma, Inc. · US
WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTER · DE

Inventors

Yan Yan · Singapore, SG
Anumeha SHAH · Cheshire, US
Ashmita SAIGAL · Stamford, US
Herman GRIFFIN · Ocilla, US
Susan Faas McKnight · Old Lyme, US
Andre Marozsan · Boston, US
Kim Askew · Lexington, US
Yvonne Nitschke · Münster, DE
Frank Rutsch · Münster, DE

Key dates

Filing date	Jun 15, 2017
Grant date	Jun 21, 2022
Priority date	—
Expiry date	Jan 18, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y301/04001
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.